Highest-materiality recent filing
Dianthus Q1 net loss $40.8M; cash $1.2B; claseprubart and DNTH212 advance
Net loss $40.8M ($0.85/share) vs $29.5M ($0.82) in Q1 2025; R&D spend $34.5M up from $27.0M.
FDA agrees to remove ANA screening, reclassify lupus risk for Dianthus' claseprubart trials
FDA agreed to remove anti-nuclear antibodies (ANAs) as screening criteria for all ongoing and future claseprubart trials.
Dianthus Therapeutics raises ~$673.5M in public offering of common stock and pre-funded warrants
Offering of 7,313,582 shares at $81.00/share and pre-funded warrants for 402,468 shares at $80.999/share.
Dianthus announces early GO decision in Phase 3 CAPTIVATE CIDP trial; reports FY2025 results
Early GO decision: 20 confirmed responders with less than 40 participants; DSMB confirmed; no serious infections or discontinuations.
Dianthus reports Q3 net loss $36.8M; gMG Ph2 data positive, CIDP Ph3 interim accelerated to Q2'26
Net loss of $36.8M ($0.97/share) vs $25.2M ($0.74/share) Q3'24; R&D $32.5M on higher clinical costs.
Dianthus licenses DNTH212 from Leads Biolabs; $30M upfront, $962M potential milestones
Up to $38M in upfront and near-term payments ($30M cash plus $8M milestone at Phase 1 start).
Dianthus raises ~$270M in public offering of common stock and pre-funded warrants
Issued 6,487,879 common shares at $33.00/share and 1,112,121 pre-funded warrants at $32.999/share.
Dianthus reports positive Phase 2 MaGic trial for claseprubart in gMG; both doses meet endpoints
Claseprubart 300mg Q2W: MG-ADL mean change -4.6 (placebo-adjusted -1.8, p=0.0113); QMG -4.4 (adj. -2.4, p=0.0144) at Week 13.
On May 22, 2025, the Board appointed Simon Read, Ph.D., as a Class III director of the Company and as a member of both the Science and Technology Committee of the Board (the “S&T” Committee) and the Nominating and Corporate Governance Committee of the Board (the “N&CG” Committee), effective immediately.
On May 22 2025, Leon O. Moulder, Jr., a member of the Board of Directors (the “Board”) of Dianthus Therapeutics, Inc. (the “Company”), notified the Company of his resignation from the Board effective immediately.
Max materiality 0.85 · Median 0.68 · Most common event other_material